Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal

International Journal of Cardiology

Volumn 180, Issue , 2015, Pages 246-254

  Lip, Gregory Y H ^a,b   Wang, Kang Ling ^c   Chiang, Chern En ^c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b AALBORG UNIVERSITY   (Denmark)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Anticoagulant; Asia; Atrial fibrillation; Stroke; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; DABIGATRAN; EDOXABAN; PLACEBO; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; VITAMIN K GROUP;

ANTICOAGULATION; ASIAN; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; COMPLICATION; ETHNOLOGY; HEALTH; INCIDENCE; ORAL DRUG ADMINISTRATION; STROKE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; GLOBAL HEALTH; HUMANS; INCIDENCE; STROKE; VITAMIN K;

EID: 84920520491     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.11.182     Document Type: Review

References (55)

1. G.Y. Lip, C.M. Brechin, and D.A. Lane The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe Chest 142 2012 1489 1498
2. H.F. Tse, Y.J. Wang, M. Ahmed Ai-Abdullah, A.B. Pizarro-Borromeo, C.E. Chiang, and R. Krittayaphong Stroke prevention in atrial fibrillation - an Asian stroke perspective Heart Rhythm. 10 2013 1082 1088
3. C.W. Siu, G.Y. Lip, K.F. Lam, and H.F. Tse Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong Heart Rhythm. 11 2014 1401 1408
4. R. De Caterina, S. Husted, L. Wallentin, F. Andreotti, H. Arnesen, and F. Bachmann Vitamin K antagonists in heart disease: current status and perspectives (section III). Position Paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease Thromb. Haemost. 110 2013 1087 1107
5. P. Gallego, V. Roldan, F. Marin, M. Romera, M. Valdes, and V. Vicente Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation Thromb. Haemost. 110 2013 1189 1198
6. A.M. Gallagher, E. Setakis, J.M. Plumb, A. Clemens, and T.P. van Staa Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients Thromb. Haemost. 106 2011 968 977
7. Y. Guo, S. Apostolakis, A.D. Blann, H. Wang, X. Zhao, and Y. Zhang Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation Int. J. Cardiol. 168 2013 904 909
8. S. Husted, R. De Caterina, F. Andreotti, H. Arnesen, F. Bachmann, and K. Huber Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel Thromb. Haemost. 111 2014 781 782
9. Determinants of warfarin use and international normalized ratio levels in atrial fibrillation patients in Japan - subanalysis of the J-RHYTHM Registry Circ. J. 75 2011 2357 2362
10. J. Amerena, S.A. Chen, C. Sriratanasathavorn, J.G. Cho, D. Huang, and R. Omar Insights into management of atrial fibrillation in Asia Pacific gained from baseline data from REgistry on cardiac rhythm disORDers (RecordAF-Asia Pacific [AP]) registry Am. J. Cardiol. 109 2012 378 382
11. H. Gamra, J. Murin, C.E. Chiang, L. Naditch-Brule, S. Brette, and P.G. Steg Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey Arch. Cardiovasc. Dis. 107 2014 77 87
12. J. Oldgren, J.S. Healey, M. Ezekowitz, P. Commerford, A. Avezum, and P. Pais Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry Circulation 129 2014 1568 1576
13. B.A. Steinberg, D.N. Holmes, M.D. Ezekowitz, G.C. Fonarow, P.R. Kowey, and K.W. Mahaffey Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry Am. Heart J. 165 2013 622 629
14. R. Nieuwlaat, A. Capucci, A.J. Camm, S.B. Olsson, D. Andresen, and D.W. Davies Atrial fibrillation management: a prospective survey in ESC Member Countries Eur. Heart J. 26 2005 2422 2434
15. J.Y. Le Heuzey, G. Breithardt, J. Camm, H. Crijns, P. Dorian, and P.R. Kowey The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation Am. J. Cardiol. 105 2010 687 693
16. M. Hori, S.J. Connolly, J. Zhu, L.S. Liu, C.P. Lau, and P. Pais Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation Stroke 44 2013 1891 1896
17. K.S. Wong, D.Y. Hu, A. Oomman, R.S. Tan, M.R. Patel, and D.E. Singer Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial Stroke 45 2014 1739 1747
18. S. Goto, J. Zhu, L. Liu, B.H. Oh, D.M. Wojdyla, and P. Aylward Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial Am. Heart J. 168 2014 303 309
19. Y. Koretsune, T. Yamashita, Y. Yang, S.A. Chen, N. Chung, and R.P. Giugliano Edoxaban versus warfarin in East-Asian (including Japanese) patients with atrial fibrillationan ENGAGE AF-TIMI 48 sub-analysis Circ. J. 78 2014 I-484
20. C.W. Siu, and H.F. Tse Net clinical benefit of warfarin therapy in elderly Chinese patients with atrial fibrillation Circ. Arrhythmia Electrophysiol. 7 2014 300 306
21. C.F. Tsai, B. Thomas, and C.L. Sudlow Epidemiology of stroke and its subtypes in Chinese vs white populations: a systematic review Neurology 81 2013 264 272
22. K.C. Teo, N.R. Mahboobani, R. Lee, C.W. Siu, R.T. Cheung, and S.L. Ho Warfarin associated intracerebral hemorrhage in Hong Kong Chinese Neurol. Res. 36 2014 143 149
23. B.F. Gage, A.D. Waterman, W. Shannon, M. Boechler, M.W. Rich, and M.J. Radford Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
24. G.Y. Lip Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? Eur. Heart J. 34 2013 1041 1049
25. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest 137 2010 263 272
26. T.F. Chao, C.J. Liu, K.L. Wang, Y.J. Lin, S.L. Chang, and L.W. Lo Using the CHA2DS2-VASc score for refining stroke risk stratification in 'low-risk' Asian patients with atrial fibrillation J. Am. Coll. Cardiol. 64 2014 1658 1665
27. B.F. Gage, Y. Yan, P.E. Milligan, A.D. Waterman, R. Culverhouse, and M.W. Rich Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF) Am. Heart J. 151 2006 713 719
28. R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J.G.M. Crijns, and G.Y.H. Lip A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation Chest 138 2010 1093 1100
29. A.J. Camm, G.Y. Lip, R. De Caterina, I. Savelieva, D. Atar, and S.H. Hohnloser 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Eur. Heart J. 33 2012 2719 2747
30. A.C. Skanes, J.S. Healey, J.A. Cairns, P. Dorian, A.M. Gillis, and M.S. McMurtry Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control Can. J. Cardiol. 28 2012 125 136
31. Center NCG Atrial Fibrillation 2014 1 418 (http://guidanceniceorguk/CG/Wave0/638)
32. J. Donze, C. Clair, B. Hug, N. Rodondi, G. Waeber, and J. Cornuz Risk of falls and major bleeds in patients on oral anticoagulation therapy Am. J. Med. 125 2012 773 778
33. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann. Intern. Med. 146 2007 857 867
34. H. Sato, K. Ishikawa, A. Kitabatake, S. Ogawa, Y. Maruyama, and Y. Yokota Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial Stroke 37 2006 447 451
35. Y. Guo, R. Pisters, S. Apostolakis, A.D. Blann, H. Wang, and X. Zhao Stroke risk and suboptimal thromboprophylaxis in Chinese patients with atrial fibrillation: would the novel oral anticoagulants have an impact? Int. J. Cardiol. 168 2013 515 522
36. D.E. Singer, A.S. Hellkamp, J.P. Piccini, K.W. Mahaffey, Y. Lokhnygina, and G. Pan Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial J. Am. Heart Assoc. 2 2013 e000067
37. H.T. Chan, L.T. So, S.W. Li, C.W. Siu, C.P. Lau, and H.F. Tse Effect of herbal consumption on time in therapeutic range of warfarin therapy in patients with atrial fibrillation J. Cardiovasc. Pharmacol. 58 2011 87 90
38. R.S. Wong, G. Cheng, and T.Y. Chan Use of herbal medicines by patients receiving warfarin Drug Saf. 26 2003 585 588
39. L. Friberg, M. Rosenqvist, and G.Y. Lip Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study Circulation 125 2012 2298 2307
40. A. Banerjee, D.A. Lane, C. Torp-Pedersen, and G.Y. Lip Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study Thromb. Haemost. 107 2012 584 589
41. C.H. Chang, Y.H. Yang, J.H. Chen, and L.J. Lin Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan Thromb. Res. 133 2014 782 789
42. H. Heidbuchel, P. Verhamme, M. Alings, M. Antz, W. Hacke, and J. Oldgren European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation Europace 15 2013 625 651
43. M.V. Huisman, G.Y. Lip, H.C. Diener, M. Brueckmann, J. van Ryn, and A. Clemens Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice Thromb. Haemost. 107 2012 838 847
44. A.G. Turpie, R. Kreutz, J. Llau, B. Norrving, and S. Haas Management consensus guidance for the use of rivaroxaban - an oral, direct factor Xa inhibitor Thromb. Haemost. 108 2012 876 886
45. T.B. Larsen, L.H. Rasmussen, F. Skjoth, K.M. Due, T. Callreus, and M. Rosenzweig Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study J. Am. Coll. Cardiol. 61 2013 2264 2273
46. Administration FaD FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin http://wwwfdagov/Drugs/DrugSafety/ucm396470htm 2014
47. L. Azoulay, S. Dell'aniello, T.A. Simon, C. Renoux, and S. Suissa Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes Eur. Heart J. 35 2014 1881 1887
48. S. Apostolakis, R.M. Sullivan, B. Olshansky, and G.Y. Lip Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score Chest 144 2013 1555 1563
49. G.Y. Lip, K. Haguenoer, C. Saint-Etienne, and L. Fauchier Relationship of the SAME-TT2R2score to poor quality anticoagulation, stroke, clinically relevant bleeding and mortality in patients with atrial fibrillation Chest 146 2014 719 726
50. D. Poli, E. Antonucci, S. Testa, and G.Y. Lip A prospective validation of the SAME-TT2R2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin Intern. Emerg. Med. 9 2014 443 447
51. P. Gallego, V. Roldan, F. Marin, J. Galvez, M. Valdes, and V. Vicente SAME-TTR score, time in therapeutic range and outcomes in anticoagulated patients with atrial fibrillation Am. J. Med. 127 2014 1083 1088
52. A. Amin, S. Deitelzweig, Y. Jing, D. Makenbaeva, D. Wiederkehr, and J. Lin Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use - learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials J. Thromb. Thrombolysis 38 2014 150 159
53. S. Lahaye, S. Regpala, S. Lacombe, M. Sharma, S. Gibbens, and D. Ball Evaluation of patients' attitudes towards stroke prevention and bleeding risk in atrial fibrillation Thromb. Haemost. 111 2014 465 473
54. D.A. Lane, and G.Y. Lip Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation Thromb. Haemost. 111 2014 381 383
55. R. Pisters, R. Nieuwlaat, D.A. Lane, H.J. Crijns, and G.Y. Lip Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey Thromb. Haemost. 109 2013 328 336